Close Menu

NEW YORK – Los Altos, California-based Quadriga BioSciences on Thursday announced that the first patient had been dosed in its Phase I, dose-escalation study of QBS10072S, a bifunctional amino acid analogue for the treatment of patients with metastatic cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.